A systematic review of clinical trials of treatment regimens in HER2-amplified metastatic colorectal cancer

Sur, Daniel; Lungulescu, Cristina; Dumitrescu, Elena Adriana; Afrăsânie, Vlad Adrian; Spînu, Ștefan; Lungulescu, Cristian Virgil; Schmoll, Hans- Joachim

doi:10.1080/14737140.2023.2207830

Cited by 2 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These targeted therapies aim to disrupt the signaling pathways driven by HER2 overexpression, ultimately inhibiting tumor growth and improving patient outcomes. However, it is important to note that not all patients with HER2 amplification respond to these therapies, and ongoing research is aimed at better understanding the subset of patients who are most likely to benefit from these treatments …”

Section: Identification Of Actionable Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Kiran,

Yashaswini,

Maheshwari

et al. 2024

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Precision medicine is transforming colorectal cancer treatment through the integration of advanced technologies and biomarkers, enhancing personalized and effective disease management. Identification of key driver mutations and molecular profiling have deepened our comprehension of the genetic alterations in colorectal cancer, facilitating targeted therapy and immunotherapy selection. Biomarkers such as microsatellite instability (MSI) and DNA mismatch repair deficiency (dMMR) guide treatment decisions, opening avenues for immunotherapy. Emerging technologies such as liquid biopsies, artificial intelligence, and machine learning promise to revolutionize early detection, monitoring, and treatment selection in precision medicine. Despite these advancements, ethical and regulatory challenges, including equitable access and data privacy, emphasize the importance of responsible implementation. The dynamic nature of colorectal cancer, with its tumor heterogeneity and clonal evolution, underscores the necessity for adaptive and personalized treatment strategies. The future of precision medicine in colorectal cancer lies in its potential to enhance patient care, clinical outcomes, and our understanding of this intricate disease, marked by ongoing evolution in the field. The current reviews focus on providing in-depth knowledge on the various and diverse approaches utilized for precision medicine against colorectal cancer, at both molecular and biochemical levels.

show abstract

Section: Identification Of Actionable Biomarkersmentioning

confidence: 99%

“…However, it is important to note that not all patients with HER2 amplification respond to these therapies, and ongoing research is aimed at better understanding the subset of patients who are most likely to benefit from these treatments. 122 3.2. Prognostic Biomarkers for Risk Assessment.…”

Section: Identification Of Actionable Biomarkersmentioning

confidence: 99%